ABOUT US |
Able Cerebral, LLC (ACL) is an innovative technology company with patents granted. We conquered technical challenges and physiological misconceptions of brain energy molecules (mainly glucose, the safest essential biological elements after air and water) to solve the unsolvable health problems like Alzheimer’s, and obesity.
Able Cerebral is the pioneer in connecting the dots between nocturnal hypoglycemia with cognitive and memory deterioration. Using our timed release of brain energy molecules as the foundation for brain energy supply, we are building an internal team and partnering with other technology enterprises to conquer the unmet challenge facing AD and MCI communities. Our flagship product BrainGlucose caplet is made with a combination of several controlled release mechanisms, which has been designed and tested for diabetes patients who are suffering from nocturnal hypoglycemia. As CDC reports, nearly three hundred thousand emergency cares due to hypoglycemia incidents annually in United States alone. Even worse, there are hundreds of millions diabetics worldwide who unaware of their nocturnal hypoglycemia, which is the silent killer of their memories. We have filed several patent applications with the USPTO and corresponding international institutions for the current and future products in the pipeline. Recently, we have been granted US and China patent for timed release of brain energy molecules.
|
|
ACL is a company with patent granted technologies in brain science. Our products can be easily adopted by home care settings. They reduce the burden of families, PCPs and the other caregivers for patients, and the cost for insurance industry and the whole society.
*ACL is a licensed manufacturer by Pennsylvania State government for our medical food products. After achieving miraculous therapy for early and mid stage Alzheimer’s patients by our flagship product BrainGlucose, Able Cerebral is migrating gradually to a pharmaceutical and medical device company in order to improve health accessibility:
|
|
In the second half of 2023, we have successfully developed a small dosage form of capsules for easy swallow. It is great news for many children and elderly customers. We plan to promote this new product in 2024 so that more patients can take advantage of this new form. We also plan to advance our AddMem project in 2024. On January 31, 2017, Temple University published a study that reveals the connection of deprivation of brain glucose and the onset of early onset of early stage of Alzheimer's disease. This is the most recent proof of our theory elucidated years ago in conferences such as AAIC Boston and AADE in Philadelphia. |
There are many Alzheimer's patients that have been gaining miraculous effects by taking out BrainGlucose caplets to eliminate nightmares, night-sweats, and hallucinations. We have presented out patient study results on the Alzheimer's Association International Conference (AAIC) 2017 in London. |
On 1-21-2021, Stanford Medicine researchers published a study in Nature. The study further proved the published results of Yale Medical from 10-19-2017 and Temple University's Med School study on 1-31-2017, that deprivation of glucose is the cause of Alzheimer's disease (AD). Even though the study did not dig deeper on why glucose converting into glycogen, it explains our BrainGlucose role in saving mid-stage AD by pushing the equilibrium towards more glucose available for energy utilization after midnight, when higher energy demanding and memory related REM dream cycles occur, and it clearly prevents the typical clinical symptoms of hallucinations, nightmares, and night-sweats of nocturnal hypoglycemia in brain. |
|
Interested Institutions for Partnership and/or Investment Please Contact:
Mr. Wayne Shentu 55 New Street, Ste. 14 Ephrata, PA 17522, U.S Tel: (717) 814-5752 [email protected] |
In memory of Professor J. Howard Rytting, diabetic and devoted his knowledge of thermodynamics to bio-pharmaceutical research.
|
|
|